The Antibody and BioResource (ABR) Core is a vibrant facility that contributes broadly to the basic and translational mission of the Center by focusing on two tools central to reproducibile research, specifically antibodies and cell lines. The Core works with researchers to develop new monoclonal antibodies (MAbs) against their target(s) of interest that will work in the required application(s). When antibodies are not readily available elsewhere, particularly newly developed at MSK, the facility provides access to essential MAbs by: 1) Producing (in vitro); 2) Purifying; 3) Conjugating (to fluorphores and proteins); and/or 4) Fragmenting them into Fab or F(Ab?)2 fragments. To promote the use of healthy cell cultures, which is central to generating reproducable data from these in vitro systems, the ABR Core offers a mycoplasma testing service. Well authenticated cell lines created at MSK and deposited into the Core are distributed to researchers around the world, which ensures the tools that the Cancer Center is sharing are of the highest quality. Relevant information and testing results on curated cell lines are also shared with recipients. These include, but are not limited to, a description and history of the line, references, culture conditions, unique characteristics, STR profiles for authentication purposes of human cell lines, images of the cells, confirmation that no mycoplasma was detectable in the culture, karyotyping, and appropriate flow cytometric analysis. During the past grant period the ABR Core has contributed to 50 publications for researchers from seven of the 10 CCSG Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-54
Application #
9858280
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Choi, Karmel W; Shaffer, Kelly M; Zale, Emily L et al. (2018) Early Risk and Resiliency Factors Predict Chronic Posttraumatic Stress Disorder in Caregivers of Patients Admitted to a Neuroscience ICU. Crit Care Med 46:713-719
Kantor, Elizabeth D; Newton, Christina C; Giovannucci, Edward L et al. (2018) Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 29:389-397
Mizrachi, Aviram; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol 78:94-101
Fassel, Hannah; Bussel, James B; Roberts, Stephen S et al. (2018) Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. J Pediatr Hematol Oncol :
Lezcano, Cecilia; Shoushtari, Alexander N; Ariyan, Charlotte et al. (2018) Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 42:1052-1058
Bello, Danielle M; Russell, Christy; McCullough, Debbie et al. (2018) Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Ann Surg Oncol 25:2884-2889
Coriddi, Michelle; Kenworthy, Elizabeth; Weinstein, Andrew et al. (2018) The importance of indocyanine green near-infrared fluorescence angiography in perfusion assessment in vascularized omentum lymphatic transplant. J Surg Oncol 118:109-112
Korenstein, Deborah; Husain, Solomon; Gennarelli, Renee L et al. (2018) Impact of Clinical Specialty on Attitudes Regarding Overuse of Inpatient Laboratory Testing. J Hosp Med 13:844-847
Wang, Lucia; Guillen, Valeria S; Sharma, Naina et al. (2018) New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS Med Chem Lett 9:803-808
Offin, Michael; Rizvi, Hira; Tenet, Megan et al. (2018) Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res :

Showing the most recent 10 out of 8799 publications